Homology Medicines, Inc.

NasdaqGS:FIXX Stock Report

Market Cap: US$54.3m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Homology Medicines Past Earnings Performance

Past criteria checks 0/6

Homology Medicines has been growing earnings at an average annual rate of 2.2%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 2.1% per year.

Key information

2.18%

Earnings growth rate

13.02%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate2.05%
Return on equity-154.76%
Net Margin-9,771.71%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Analysis Article • Nov 16

Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 06

Homology Medicines appoints new CEO, chairperson

Genetic medicines company Homology Medicines (NASDAQ:FIXX) promoted Chief Scientific Officer Albert Seymour to the position of CEO, president and board member. Seymour succeeds Arthur Tzianabos, who has been appointed as chairperson. Source: Press Release
Seeking Alpha • Jul 05

Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid

Homology Medicines (NASDAQ:FIXX) on Tuesday announced peer-reviewed publication of data on its AAVHSC16 capsid. FIXX stock earlier gained as much as 9.8% to a session high of $2.01 and was last up 3.3% in afternoon trading. According to the data, AAVHSC16 showed low levels of tropism to the liver while maintaining robust distribution to the central nervous system (CNS) and peripheral organs following a single intravenous injection in preclinical studies with rodents and primates. The preclinical data was peer-reviewed and published in the Molecular Therapy - Methods & Clinical Development journal. AAVHSC16 is a capsid, which is the protein shell of a virus that encloses its genetic material. AAVHSC stands for adeno-associated virus and hematopoietic stem cells, which are naturally occurring stem cells. FIXX's technology uses a family of 15 these types of cells to deliver genetic medicines. "In the case of AAVHSC16 with its ability to reach key tissues without targeting the liver in preclinical models, we can potentially expand into additional disease areas where we want to deliver to the CNS, cardiac tissue, or muscle while avoiding exposure in the liver," said FIXX chief scientific officer Albert Seymour.
Analysis Article • Jan 28

Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 22

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Homology Medicines has built a unique gene therapy platform but has experienced a significant stock price decrease due to a COVID-related trial delay and controversy over its gene editing applications. The investment opportunity is to buy the stock on the premise that a resumption of the lead phase 2 trial will act as a positive catalyst for the stock price. The lead drug candidate, HMI-102, has the potential to become the standard-of-care in phenylketonuria, and any catalysts are likely to close the current valuation gap. Beyond the lead trial, Homology's platform has the potential to expand to CNS disorders, ophthalmological diseases, lung diseases, and more.
Analysis Article • Sep 18

We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 14

Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%

Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • May 22

Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts

Celebrations may be in order for Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders, with the analysts delivering a...
Analysis Article • Apr 17

Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 13

Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?

Every investor in Homology Medicines, Inc. ( NASDAQ:FIXX ) should be aware of the most powerful shareholder groups...
Analysis Article • Feb 03

Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year

Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders should be happy to see the share price up 18% in the last...

Revenue & Expenses Breakdown

How Homology Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:FIXX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231-113300
30 Sep 232-131320
30 Jun 233-132320
31 Mar 233-126320
31 Dec 223-5380
30 Sep 223-4410
30 Jun 224-1410
31 Mar 225-3420
31 Dec 2134-96370
30 Sep 2134-92340
30 Jun 2133-90340
31 Mar 2131-94330
31 Dec 203-129330
30 Sep 202-123310
30 Jun 202-124280
31 Mar 202-115250
31 Dec 192-104220
30 Sep 192-99220
30 Jun 193-83190
31 Mar 194-69180
31 Dec 185-56170
30 Sep 184-49150
30 Jun 183-41130
31 Mar 181-35100
31 Dec 170-3080

Quality Earnings: FIXX is currently unprofitable.

Growing Profit Margin: FIXX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: FIXX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare FIXX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FIXX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).

Return on Equity

High ROE: FIXX has a negative Return on Equity (-154.76%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/26 02:46
End of Day Share Price 2024/03/25 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Homology Medicines, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Jason ZemanskyBofA Global Research
Madhu KumarB. Riley Securities, Inc.